[MIC2 (CD99) as a diagnostic marker for TdT-negative B lymphoblastic lymphoma].

Ikeda, Naoto; Imao, Takeshi; Hisano, Yuki; Kamao, Takayuki; Uno, Masatoshi; Mizushima, Takaaki

Ikeda, Naoto; Imao, Takeshi; Hisano, Yuki; Kamao, Takayuki; Uno, Masatoshi; Mizushima, Takaaki.

Afiliación

Ikeda N; Department of Internal Medicine, Kaneda Hospital.
Imao T; Department of Internal Medicine, Kaneda Hospital.
Hisano Y; Department of Internal Medicine, Kaneda Hospital.
Kamao T; Department of Internal Medicine, Kaneda Hospital.
Uno M; Department of Internal Medicine, Kaneda Hospital.
Mizushima T; Department of Internal Medicine, Kaneda Hospital.

Rinsho Ketsueki ; 64(2): 130-132, 2023.

Article en Ja | MEDLINE | ID: mdl-36990733

Asunto(s)

Neoplasias Hematológicas; Linfoma no Hodgkin; Leucemia-Linfoma Linfoblástico de Células Precursoras; Anciano; Humanos; Masculino; Antígeno 12E7; Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico; ADN Nucleotidilexotransferasa/metabolismo

Palabras clave

CD99; Lymphoblastic lymphoma; MIC2; Terminal deoxynucleotidyl transferase

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Neoplasias Hematológicas / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Diagnostic_studies Límite: Aged / Humans / Male Idioma: Ja Revista: Rinsho Ketsueki Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google